144 related articles for article (PubMed ID: 7712676)
1. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
[TBL] [Abstract][Full Text] [Related]
2. The variability of orocecal transit time evaluated by the salicylazosulphapyridine/sulphapyridine method.
Gramatté T; Terhaag B
Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):147-50. PubMed ID: 1676990
[TBL] [Abstract][Full Text] [Related]
3. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
Bates TR; Blumenthal HP; Pieniaszek HJ
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
[TBL] [Abstract][Full Text] [Related]
4. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
[No Abstract] [Full Text] [Related]
5. [Comparative effects of ricinoleic acid and senna on orocecal and oroanal transit time in healthy subjects. Application of the salacylazosulfapyridine method].
Sogni P; Chaussade S; Akue-Gohe K; Nepveux P; Homerin M; Couturier D; Guerre J
Gastroenterol Clin Biol; 1992; 16(1):21-4. PubMed ID: 1347025
[TBL] [Abstract][Full Text] [Related]
6. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Bates TR; Blumenthal HP; Pieniaszek HJ
Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
[TBL] [Abstract][Full Text] [Related]
8. Influence of age and body size on orocecal transit time as assessed by use of the sulfasalazine method in healthy dogs.
Weber MP; Martin LJ; Biourge VC; Nguyen PG; Dumon HJ
Am J Vet Res; 2003 Sep; 64(9):1105-9. PubMed ID: 13677387
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys.
Kondo H; Watanabe T; Yokohama S; Watanabe J
Biopharm Drug Dispos; 2003 May; 24(4):141-51. PubMed ID: 12698497
[TBL] [Abstract][Full Text] [Related]
10. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
Day JM; Houston JB
Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
[No Abstract] [Full Text] [Related]
11. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit.
Agrawal A; Houghton LA; Reilly B; Morris J; Whorwell PJ
Am J Gastroenterol; 2009 Aug; 104(8):1998-2004. PubMed ID: 19491831
[TBL] [Abstract][Full Text] [Related]
12. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
[TBL] [Abstract][Full Text] [Related]
13. Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects.
Addolorato G; Montalto M; Capristo E; Certo M; Fedeli G; Gentiloni N; Stefanini GF; Gasbarrini G
Hepatogastroenterology; 1997; 44(16):1076-81. PubMed ID: 9261602
[TBL] [Abstract][Full Text] [Related]
14. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.
Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML
Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075
[TBL] [Abstract][Full Text] [Related]
15. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
16. A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs.
Papasouliotis K; Gruffydd-Jones TJ; Sparkes AH; Cripps PJ
Res Vet Sci; 1995 May; 58(3):263-7. PubMed ID: 7659853
[TBL] [Abstract][Full Text] [Related]
17. [Modification of orocecal transit time of salazosulfapyridine by atropine and metoclopramide in healthy probands].
Terhaag B; Neugebauer A
Dtsch Z Verdau Stoffwechselkr; 1986; 46(6):327-32. PubMed ID: 2881772
[TBL] [Abstract][Full Text] [Related]
18. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
Sjödin L; Visser S; Al-Saffar A
J Pharmacol Toxicol Methods; 2011; 64(1):42-52. PubMed ID: 21596146
[TBL] [Abstract][Full Text] [Related]
19. Effect of clonidine on gastrointestinal transit time.
Mann NS; Shinkle JM
Hepatogastroenterology; 1998; 45(22):1023-5. PubMed ID: 9756001
[TBL] [Abstract][Full Text] [Related]
20. Sluggish small bowel motility is involved in determining increased biliary deoxycholic acid in cholesterol gallstone patients.
Azzaroli F; Mazzella G; Mazzeo C; Simoni P; Festi D; Colecchia A; Montagnani M; Martino C; Villanova N; Roda A; Roda E
Am J Gastroenterol; 1999 Sep; 94(9):2453-9. PubMed ID: 10484008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
